Skip to Content

Gregory N Fuller, M.D., Ph.D.

Present Title & Affiliation

Primary Appointment

Professor, with Tenure, Department of Pathology, Division of Pathology/Lab Medicine, MD Anderson Cancer Center, Houston, TX
Chief, Section of Neuropathology, Department of Pathology, Division of Pathology/Lab Medicine, MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1987 Baylor College of Medicine, Houston, TX, MD, Medicine
1983 University of Texas Graduate School of Biomedical Sciences (Houston), Houston, TX, PhD, Biomedical Science / Neuroscience

Postgraduate Training

1990-1992 Fellowship (Neuropathology), Duke University, Durham, NC, F. Stephen Vogel, Peter C. Burger, Darrell D. Bigner
1988-1990 Residency (Anatomic Pathology), Duke University, Durham, NC
1987-1988 Internship (Pathology), Duke University, Durham, NC

Board Certifications

6/1994 American Board of Pathology, Combined Anatomic Pathology and Neuropathology


Administrative Appointments/Responsibilities

Co-Director, MDACC/Methodist-Cornell Neuropathology Fellowship, MDACC-Methodist Hospital Neuropathology Fellowship Program, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2005-present
Member, Executive Committee, Department of Pathology, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2004-present
Director, Automated Image Analysis Core Laboratory, Department of Pathology, Division of Pathology/Lab Medicine, MD Anderson Cancer Center, Houston, TX, 4/2001-present

Institutional Committee Activities

Member, PRS Executive Committee, 9/2014-present
Member, Search Committee for Chair of the Department of Pathology, 12/2011-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Elllezam B, Theeler BJ, Walbert T, Mammoser A, Horbinski C, Kleinschmidt-DeMasters BK, Perry A, Puduvalli V, Fuller GN, Bruner JB, Aldape KD. Low rate of R132H IDH1 mutation in infratentorial and spinal cord grad II and III diffuse gliomas. Acta Neuropathol,. In Press.
2. Hightower E, Cabanillas M, Fuller GN, McCutcheon I, Hess K, Shah K, Waguespack S, Corley L, Devin J. Phospho-histone H3 (PHH3) Immuno-reactivity as a Prognostic Marker in Non-Functioning Pituitary Adenomas. Pituitary. In Press.
3. Jonasch E, McCutcheon IE, Waguespack SG, Wen S, Do KA, Davis DW, Zhang Y, Smith L, Tamboli P, Tannir NM, Gombos DS, Fuller GN. Pilot Trial of Sunitinib Theraphy in Patients with von Hippel-Lindau Disease. Annals of Oncology. In Press.
4. Lee I, Fox P, Ferguson S, Bassett R, Yuan Kong L, Schacherer C, Gershenwald JE,Grimm EA, Fuller GN, Heimberger A. The expression of p-STAT3 in Stage IV Melanoma: Risk of CNS Metastasis and Survival. In Press.
5. Gressot LV, Doucette TA, Yang Y, Fuller GN, Heimberger AB, Bögler O, Rao A, Latha K, Rao G. Signal transducer and activator of transcription 5b drives malignant progression in a PDGFB-dependent proneural glioma model by suppressing apoptosis. Int J Cancer 136(9):2047-54, 5/2015. e-Pub 10/2014. PMCID: PMC4331224.
6. Chua CY, Liu Y, Granberg KJ, Hu L, Haapasalo H, Annala MJ, Cogdell DE, Verploegen M, Moore LM, Fuller GN, Nykter M, Cavenee WK, Zhang W. IGFBP2 potentiates nuclear EGFR-STAT3 signaling. Oncogene. e-Pub 4/2015. PMID: 25893308.
7. Turner KM, Sun Y, Ji P, Granberg KJ, Bernard B, Hu L, Cogdell DE, Zhou X, Yli-Harja O, Nykter M, Shmulevich I, Yung WK, Fuller GN, Zhang W. Genomically amplified Akt3 activates DNA repair pathway and promotes glioma progression. Proc Natl Acad Sci U S A 112(11):3421-6, 3/2015. e-Pub 3/2015. PMCID: PMC4371922.
8. Louis DN, Perry A, Burger P, Ellison DW, Reifenberger G, von Deimling A, Aldape K, Brat D, Collins VP, Eberhart C, Figarella-Branger D, Fuller GN, Giangaspero F, Giannini C, Hawkins C, Kleihues P, Korshunov A, Kros JM, Beatriz Lopes M, Ng HK, Ohgaki H, Paulus W, Pietsch T, Rosenblum M, Rushing E, Soylemezoglu F, Wiestler O, Wesseling P, International Society Of Neuropathology--Haarlem. International Society of Neuropathology-Haarlem Consensus Guidelines, for Nervous System Tumor Classification and Grading. Brain Pathol 24(5):429-35, 9/2014. e-Pub 9/2014. PMID: 24990071.
9. Gottesfeld Z, Fuller GN , Wiggins RC. Adrenergic neuroplasticity is maintained in the nutritional rehabilitated adult rat. Experientia 37(2):168-9, 2/1981. PMID: 7238746.
10. Taber KH, Fuller GN, Stanley JC, DeFrance JF, Wiggins RC. The effect of postnatal undernourishment on epileptiform kindling of dorsal hippocampus. Experientia 36(1):69-70, 1/1980. PMID: 7358137.
11. Wiggins RC, Fuller GN, Astrello JM, Rigor BM. Decreased myelin synthesis in developing rats following repeated pre- and perinatal exposure to subanesthetic amounts of halothane. J Neurochem 33(1):361-3, 7/1979. PMID: 458464.
12. Wiggins RC, Fuller GN, Bell ME. Incorporation of leucine metabolites into brain and sciatic nerve myelin. J Neurochem 32(5):1579-82, 5/1979. PMID: 438825.
13. Wiggins RC, Fuller GN. Early postnatal starvation causes lasting brain hypomyelination. J Neurochem 30(6):1231-7, 6/1978. PMID: 670966.

Grant & Contract Support

Title: Implications of a novel glioblastoma classification defined by miR-21-Sox2 status
Funding Source: NIH/NCI
Role: Collaborator
Duration: 9/1/2012 - 5/31/2016
Title: Dissecting glioma genesis through a glial-specific mouse model (This is the renewal of the RO1 currently on no-cost extension)
Funding Source: NIH/NCI
Role: Co-Principal Investigator
Duration: 1/1/2010 - 12/31/2014
Title: Validating the IGFBP2-ILK-NFkB pathway in glioma development and progression by a glial specific mouse model
Funding Source: Goldhirsh Foundation
Role: Co-Principal Investigator
Duration: 7/1/2008 - 6/30/2011
Title: New Mechanisms of and Mouse Models for Medulloblastoma
Funding Source: NIH/NCI
Role: Collaborator
Duration: 9/17/2002 - 6/30/2015
Title: Bullock Memorial Fund for Neurosurgery
Funding Source: Anthony Bullock III Research Fund
Role: Co-Principal Investigator
Duration: 2/1/2002 - present

Last updated: 7/31/2015